ポイントオブケア薬物乱用検査市場規模、シェア、動向分析レポート：製品別、サンプルタイプ別、技術別、最終用途別、地域別、セグメント別予測、2025年～2033年

ポイントオブケア（POC）薬物乱用（DOA）検査市場概要

世界のPOC薬物乱用検査市場規模は、2024年に10億8,000万米ドルと推定され、2025～2033年にかけてCAGR 9.62%で成長し、2033年には24億5,000万米ドルに達すると予測されます。尿、唾液、呼気、汗ベースキットを含むPOC検査は、サンプル採取現場で迅速な結果を提供するため、複雑なラボインフラを必要としないです。

これらのツールは、臨床現場、道路脇の取締り、学校、さらには家庭でも採用されるようになってきており、世界的に公衆衛生と安全戦略の重要な要素となっています。技術の進歩は、POC DOA検査装置の精度、スピード、使いやすさを大幅に向上させています。イムノアッセイベーステストストリップ、ポータブル分析装置、デジタルリーダーの開発により、最小限のサンプル処理で迅速な結果が得られるようになりました。AIと機械学習がいくつかの検査プラットフォームに統合され始めており、結果の解釈を支援し、オペレーターのミスを減らしています。経口液や発汗ベース検査など、非侵襲的なサンプリング方法は、ユーザーのコンプライアンスとプライバシーを向上させています。さらに、新しい装置はマルチパネル薬物検査をサポートするようになり、オピオイド、大麻、コカイン、アンフェタミン、ベンゾジアゼピンなどの複数の物質を同時に検出できるようになりました。このような技術革新は、救急部、警察、リハビリテーションセンターなど、迅速な意思決定が不可欠な環境では極めて重要です。診断技術の小型化と、スマートフォンとの統合やBluetooth対応データロギングを含む接続機能の向上により、これらのツールはより身近で使いやすくなり、専門家市場と消費者市場の両方での採用が進んでいます。

政府の規制と職場の安全への取り組みは、POC DOA検査市場拡大の主要な促進要因です。米国のような国々では、連邦政府の義務として、運輸、航空、ヘルスケアなどの安全が重視される産業に対して薬物スクリーニングが義務付けられています。このため、陽性結果が出ない限り検査室での確認が必要なく、迅速なスクリーニングを提供する現場検査キットが広く使用されるようになりました。路上での薬物検査プログラム、特に大麻の使用が合法化された管轄区域では、正確で移動可能なPOC装置の需要も高まっています。さらに、学校の薬物防止プログラムや軍の採用プロセスでは、薬物使用を抑止し早期に特定するために、迅速なスクリーニング方法を取り入れるケースが増えています。欧州のとアジアの一部では、職場の安全に関する法律とアンチ・ドーピングの取り組みが発展しており、より広範な実施を支えています。こうした枠組みは、公共の安全を促進するだけでなく、さまざまな分散型環境で展開できる、信頼性が高く、費用対効果が高く、使いやすい検査ソリューションに対する着実な需要を生み出しています。

プライバシー、利便性、自己モニタリングに対する要求の高まりは、自宅でのDOA検査の大幅な増加につながっています。これらのキットは、唾液、尿、毛髪のサンプルを使って、個人的な環境で自分自身や他人を検査することを可能にします。COVID-19の大流行は、消費者とヘルスケア提供者が遠隔で健康をモニターする方法を探したため、自己検査モデルの採用をさらに加速させました。遠隔医療サービスは、中毒治療や疼痛管理を受ける患者のためにこれらのキットを取り入れ、ケアの継続性を高めています。

目次

第1章 ポイントオブケア薬物乱用検査市場：調査手法と範囲

第2章 ポイントオブケア薬物乱用検査市場：エグゼクティブサマリー

• 市場スナップショット
• 製品と用途のスナップショット
• テストタイプのスナップショット
• 競合情勢のスナップショット

第3章 ポイントオブケア薬物乱用検査市場の変数、動向、範囲

• 市場セグメンテーションと範囲
• 市場系統の展望
  • 親市場の展望
  • 関連/補助市場展望
• 市場力学
• 市場促進要因分析
  • 薬物乱用率の上昇
  • 検査装置の技術的進歩
  • 分散型テストへの関心の高まり
• 市場抑制要因分析
  • 偽陽性/偽陰性のリスク
  • 規制と償還の課題
• ポーターのファイブフォース分析
• PESTLE分析
• パイプライン分析

第4章 ポイントオブケア薬物乱用検査市場：製品別、推定・動向分析

• ポイントオブケア薬物乱用検査市場：製品変動分析
• 免疫測定テストストリップとカセット
• 口腔液検査キット
• 呼気分析装置
• 尿収集カップ
• デジタル/ポータブルアナライザ

第5章 ポイントオブケア薬物乱用検査市場：サンプルタイプ別、推定・動向分析

• ポイントオブケア薬物乱用検査市場：サンプルタイプ変動分析
• 尿
• 唾液（口腔液）
• 呼吸
• 血液
• 汗/髪

第6章 ポイントオブケア薬物乱用検査市場：技術別、推定・動向分析

• ポイントオブケア薬物乱用検査市場：技術変動分析
• ラテラルフローアッセイ（LFA）
• クロマトグラフィー免疫測定
• 酵素免疫測定（ELISA）
• 質量分析（ポータブルまたはハイブリッドPOCユニット）

第7章 ポイントオブケア薬物乱用検査市場：最終用途別、推定・動向分析

• ポイントオブケア薬物乱用検査市場：最終用途変動分析
• 病院と救急科
• 職場・労働衛生センター
• 在宅医療とリモートユーザー
• その他

第8章 ポイントオブケア薬物乱用検査市場：地域ビジネス分析

• 地域市場のスナップショット
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東・アフリカ

第9章 競合情勢

• 企業分類
• 戦略マッピング
  • 新製品発売
  • パートナーシップ
  • 取得
  • コラボレーション
  • 資金調達
• 主要企業の市場シェア分析（2024年）
• 企業ヒートマップ分析
• 企業プロファイル
  • ABBOTT
  • QUEST DIAGNOSTICS
  • THERMO FISHER SCIENTIFIC
  • ORASURE TECHNOLOGIES
  • SIEMENS HEALTHINEERS
  • F. HOFFMANN-LA ROCHE LTD.
  • Dragerwerk AG & Co. KGaA
  • LABCORP（LABORATORY CORPORATION OF AMERICA HOLDINGS）
  • PREMIER BIOTECH, INC.

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviation
• Table 3 Global Point of Care Drug of Abuse (DOA) Testing Market, By Region, 2021 - 2033 (USD Million)
• Table 4 Global Point of Care Drug of Abuse (DOA) Testing Market, By Sample Type, 2021 - 2033 (USD Million)
• Table 5 Global Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
• Table 6 Global Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
• Table 7 Global Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
• Table 8 North America Point of Care Drug of Abuse (DOA) Testing Market, By Country, 2021 - 2033 (USD Million)
• Table 9 North America Point of Care Drug of Abuse (DOA) Testing Market, By Sample Type, 2021 - 2033 (USD Million)
• Table 10 North America Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
• Table 11 North America Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
• Table 12 North America Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
• Table 13 U.S. Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
• Table 14 U.S. Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
• Table 15 U.S. Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
• Table 16 U.S. Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
• Table 17 Canada Point of Care Drug of Abuse (DOA) Testing Market, By Sample Type, 2021 - 2033 (USD Million)
• Table 18 Canada Point of Care Drug of Abuse (DOA) Testing Market, by Product, 2021 - 2033 (USD Million)
• Table 19 Canada Point of Care Drug of Abuse (DOA) Testing Market, by Technology, 2021 - 2033 (USD Million)
• Table 20 Canada Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
• Table 21 Mexico Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
• Table 22 Mexico Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
• Table 23 Mexico Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
• Table 24 Mexico Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
• Table 25 Europe Point of Care Drug of Abuse (DOA) Testing Market, by country, 2021 - 2033 (USD Million)
• Table 26 Europe Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
• Table 27 Europe Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
• Table 28 Europe Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
• Table 29 Europe Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
• Table 30 UK Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
• Table 31 UK Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
• Table 32 UK Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
• Table 33 UK Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
• Table 34 Germany Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
• Table 35 Germany Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
• Table 36 Germany Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
• Table 37 Germany Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
• Table 38 France Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
• Table 39 France Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
• Table 40 France Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
• Table 41 France Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
• Table 42 Italy Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
• Table 43 Italy Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
• Table 44 Italy Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
• Table 45 Italy Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
• Table 46 Spain Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
• Table 47 Spain Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
• Table 48 Spain Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
• Table 49 Spain Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
• Table 50 Sweden Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
• Table 51 Sweden Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
• Table 52 Sweden Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
• Table 53 Sweden Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
• Table 54 Norway Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
• Table 55 Norway Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
• Table 56 Norway Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
• Table 57 Norway Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
• Table 58 Denmark Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
• Table 59 Denmark Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
• Table 60 Denmark Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
• Table 61 Denmark Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
• Table 62 Asia Pacific Point of Care Drug of Abuse (DOA) Testing Market, by country, 2021 - 2033 (USD Million)
• Table 63 Asia Pacific Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
• Table 64 Asia Pacific Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
• Table 65 Asia Pacific Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
• Table 66 Asia Pacific Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
• Table 67 Japan Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
• Table 68 Japan Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
• Table 69 Japan Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
• Table 70 Japan Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
• Table 71 China Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
• Table 72 China Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
• Table 73 China Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
• Table 74 China Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
• Table 75 India Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
• Table 76 India Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
• Table 77 India Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
• Table 78 India Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
• Table 79 Australia Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
• Table 80 Australia Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
• Table 81 Australia Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
• Table 82 Australia Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
• Table 83 Thailand Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
• Table 84 Thailand Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
• Table 85 Thailand Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
• Table 86 Thailand Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
• Table 87 South Korea Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
• Table 88 South Korea Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
• Table 89 South Korea Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
• Table 90 South Korea Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
• Table 91 Latin America Point of Care Drug of Abuse (DOA) Testing Market, by country, 2021 - 2033 (USD Million)
• Table 92 Latin America Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
• Table 93 Latin America Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
• Table 94 Latin America Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
• Table 95 Latin America Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
• Table 96 Brazil Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
• Table 97 Brazil Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
• Table 98 Brazil Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
• Table 99 Brazil Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
• Table 100 Argentina Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
• Table 101 Argentina Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
• Table 102 Argentina Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
• Table 103 Argentina Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
• Table 104 MEA Point of Care Drug of Abuse (DOA) Testing Market, by country, 2021 - 2033 (USD Million)
• Table 105 MEA Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
• Table 106 MEA Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
• Table 107 MEA Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
• Table 108 MEA Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
• Table 109 South Africa Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
• Table 110 South Africa Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
• Table 111 South Africa Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
• Table 112 South Africa Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
• Table 113 Saudi Arabia Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
• Table 114 Saudi Arabia Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
• Table 115 Saudi Arabia Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
• Table 116 Saudi Arabia Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
• Table 117 UAE Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD Million)
• Table 118 UAE Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
• Table 119 UAE Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
• Table 120 UAE Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)
• Table 121 Kuwait Point of Care Drug of Abuse (DOA) Testing Market, by Sample Type, 2021 - 2033 (USD)
• Table 122 Kuwait Point of Care Drug of Abuse (DOA) Testing Market, By Product, 2021 - 2033 (USD Million)
• Table 123 Kuwait Point of Care Drug of Abuse (DOA) Testing Market, By Technology, 2021 - 2033 (USD Million)
• Table 124 Kuwait Point of Care Drug of Abuse (DOA) Testing Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Information procurement
• Fig. 3 Market summary
• Fig. 4 Market segmentation & scope
• Fig. 5 Market size and growth prospects
• Fig. 6 Global point of care drug of abuse (DOA) testing market - Key market driver analysis
• Fig. 7 Global point of care drug of abuse (DOA) testing market - Key market restraint analysis
• Fig. 8 Penetration & growth prospect mapping
• Fig. 9 Global point of care drug of abuse (DOA) testing market - Porter's analysis
• Fig. 10 Global point of care drug of abuse (DOA) testing market - PESTEL analysis
• Fig. 11 Global point of care drug of abuse (DOA) testing market product outlook key takeaways
• Fig. 12 Global point of care drug of abuse (DOA) testing market: Product movement analysis
• Fig. 13 Immunoassay Test Strips and Cassettes
• Fig. 14 Oral Fluid Testing Kits market estimates, 2021 - 2033 (USD Million)
• Fig. 15 Breath Analyzers market estimates, 2021 - 2033 (USD Million)
• Fig. 16 Urine Collection Cups market estimates, 2021 - 2033 (USD Million)
• Fig. 17 Digital/Portable Analyzers market estimates, 2021 - 2033 (USD Million)
• Fig. 18 Global point of care drug of abuse (DOA) testing market sample type outlook key takeaways
• Fig. 19 Global point of care drug of abuse (DOA) testing market: sample type movement analysis
• Fig. 20 Urine market estimates, 2021 - 2033 (USD Million)
• Fig. 21 Saliva (Oral Fluid) market estimates, 2021 - 2033 (USD Million)
• Fig. 22 Breath market estimates, 2021 - 2033 (USD Million)
• Fig. 23 Blood market estimates, 2021 - 2033 (USD Million)
• Fig. 24 Sweat/Hair market estimates, 2021 - 2033 (USD Million)
• Fig. 25 Global point of care drug of abuse (DOA) testing market technology outlook key takeaways
• Fig. 26 Global point of care drug of abuse (DOA) testing market: technology movement analysis
• Fig. 27 Lateral Flow Assay (LFA) market estimates, 2021 - 2033 (USD Million)
• Fig. 28 Chromatographic Immunoassays market estimates, 2021 - 2033 (USD Million)
• Fig. 29 Enzyme-Linked Immunosorbent Assay (ELISA) market estimates, 2021 - 2033 (USD Million)
• Fig. 30 Mass Spectrometry (portable or hybrid POC units) market estimates, 2021 - 2033 (USD Million)
• Fig. 31 Global point of care drug of abuse (DOA) testing market end use outlook key takeaways
• Fig. 32 Global point of care drug of abuse (DOA) testing market: sample type movement analysis
• Fig. 33 Urine market estimates, 2021 - 2033 (USD Million)
• Fig. 34 Regional marketplace: Key takeaways
• Fig. 35 Global point of care drug of abuse (DOA) testing market: Regional movement analysis
• Fig. 36 North America point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
• Fig. 37 U.S. point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
• Fig. 38 Canada point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
• Fig. 39 Mexico point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
• Fig. 40 Europe point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
• Fig. 41 UK point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
• Fig. 42 Germany point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
• Fig. 43 France point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
• Fig. 44 Spain point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
• Fig. 45 Italy point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
• Fig. 46 Denmark point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
• Fig. 47 Sweden point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
• Fig. 48 Norway point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
• Fig. 49 Asia Pacific point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
• Fig. 50 Japan point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
• Fig. 51 China point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
• Fig. 52 India point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
• Fig. 53 South Korea point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
• Fig. 54 Australia point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
• Fig. 55 Thailand point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
• Fig. 56 Latin America point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
• Fig. 57 Brazil point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
• Fig. 58 Argentina point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
• Fig. 59 MEA point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
• Fig. 60 South Africa point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
• Fig. 61 Saudi Arabia point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
• Fig. 62 UAE point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
• Fig. 63 Kuwait point of care drug of abuse (DOA) testing market, 2021 - 2033 (USD Million)
• Fig. 64 Strategy framework

Point Of Care Drug Of Abuse Testing Market Summary

The global point of care drug of abuse testing market size was estimated at USD 1.08 billion in 2024 and is projected to reach USD 2.45 billion by 2033, growing at a CAGR of 9.62% from 2025 to 2033, due to increasing substance misuse worldwide and the urgent need for rapid, decentralized drug testing solutions. POC testing, which includes urine, saliva, breath, and sweat-based kits, provides rapid results at the site of sample collection, eliminating the need for complex lab infrastructure.

These tools are increasingly being adopted in clinical settings, roadside enforcement, schools, and even at home, making them a key component in public health and safety strategies globally. Technological advancements are significantly enhancing the accuracy, speed, and usability of POC DOA testing devices. The development of immunoassay-based test strips, portable analyzers, and digital readers enables fast results with minimal sample handling. AI and machine learning are beginning to integrate into some testing platforms, assisting in result interpretation and reducing operator error. Non-invasive sampling methods, such as oral fluid and sweat-based testing, are improving user compliance and privacy. In addition, newer devices now support multi-panel drug testing, enabling simultaneous detection of multiple substances such as opioids, cannabis, cocaine, amphetamines, and benzodiazepines. These innovations are crucial in settings where quick decision-making is essential-such as emergency departments, law enforcement operations, and rehabilitation centers. The miniaturization of diagnostic technology and improved connectivity features, including smartphone integration and Bluetooth-enabled data logging, are making these tools more accessible and user-friendly, driving adoption in both professional and consumer markets.

Government regulations and workplace safety initiatives are key drivers in the expansion of the POC DOA testing market. In countries such as the U.S., federal mandates require drug screening for safety-sensitive industries such as transportation, aviation, and healthcare. This has led to widespread use of on-site testing kits that provide rapid screening without needing laboratory confirmation unless a positive result arises. Roadside drug testing programs, particularly in jurisdictions with legalized cannabis use, are also boosting demand for accurate and mobile POC devices. Moreover, school drug prevention programs and military recruitment processes increasingly incorporate quick screening methods to deter and identify drug use early. In Europe and parts of Asia, evolving workplace safety laws and anti-doping initiatives are supporting broader implementation. These frameworks not only promote public safety but also create a steady demand for reliable, cost-effective, and easy-to-use testing solutions that can be deployed in a range of decentralized environments.

The growing demand for privacy, convenience, and self-monitoring has led to a significant rise in at-home DOA testing. These kits allow individuals to test themselves or others in private settings using saliva, urine, or hair samples. The COVID-19 pandemic further accelerated the adoption of self-testing models, as consumers and healthcare providers looked for ways to monitor health remotely. Telehealth services have incorporated these kits for patients undergoing addiction treatment or pain management, enhancing continuity of care.

Global Point of Care Drug of Abuse Testing Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global point of care drug of abuse testing market based on product, technology, sample type, end use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Immunoassay Test Strips and Cassettes
• Oral Fluid Testing Kits
• Breath Analyzers
• Urine Collection Cups
• Digital/Portable Analyzers
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Lateral Flow Assay (LFA)
• Chromatographic Immunoassays
• Enzyme-Linked Immunosorbent Assay (ELISA)
• Mass Spectrometry (portable or hybrid POC units)
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals & Emergency Departments
• Workplace & Occupational Health Center
• Home Care & Remote Users
• Others
• Sample Type Outlook (Revenue, USD Million, 2021 - 2033)
• Urine
• Saliva (Oral Fluid)
• Breath
• Blood
• Sweat/Hair
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Point of Care Drug of Abuse (DOA) Testing Market: Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Product Segment
    • 1.1.1.2. Application Segment
    • 1.1.1.3. Test Type segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Point of Care Drug of Abuse (DOA) Testing Market: Executive Summary

• 2.1. Market Snapshot
• 2.2. Product and Application Snapshot
• 2.3. Test Type Snapshot
• 2.4. Competitive Landscape Snapshot

Chapter 3. Point of Care Drug of Abuse (DOA) Testing Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers Analysis
  • 3.4.1. Rising Substance Abuse Rates
  • 3.4.2. Technological Advancements in Testing Devices
  • 3.4.3. Growing Preference for Decentralized Testing
• 3.5. Market Restraint Analysis
  • 3.5.1. Risk of False Positives/Negatives
  • 3.5.2. Regulatory and Reimbursement Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis
• 3.8. Pipeline Analysis

Chapter 4. Point of Care Drug of Abuse (DOA) Testing Market: Product Estimates & Trend Analysis

• 4.1. Point of Care Drug of Abuse (DOA) Testing Market: Product Movement Analysis
• 4.2. Immunoassay Test Strips and Cassettes
• 4.3. Oral Fluid Testing Kits
  • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.4. Breath Analyzers
  • 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Urine Collection Cups
  • 4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Digital/Portable Analyzers
  • 4.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Point of Care Drug of Abuse (DOA) Testing Market: Sample Type Estimates & Trend Analysis

• 5.1. Point of Care Drug of Abuse (DOA) Testing Market: Sample Type Movement Analysis
• 5.2. Urine
  • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.3. Saliva (Oral Fluid)
  • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.4. Breath
  • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Blood
  • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Sweat/Hair
  • 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Point of Care Drug of Abuse (DOA) Testing Market: Technology Estimates & Trend Analysis

• 6.1. Point of Care Drug of Abuse (DOA) Testing Market: Technology Movement Analysis
• 6.2. Lateral Flow Assay (LFA)
  • 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.3. Chromatographic Immunoassays
  • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.4. Enzyme-Linked Immunosorbent Assay (ELISA)
  • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Mass Spectrometry (portable or hybrid POC units)
  • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Point of Care Drug of Abuse (DOA) Testing Market: End Use Estimates & Trend Analysis

• 7.1. Point of Care Drug of Abuse (DOA) Testing Market: End Use Movement Analysis
• 7.2. Hospitals & Emergency Departments
  • 7.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.3. Workplace & Occupational Health Center
  • 7.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.4. Home Care & Remote Users
  • 7.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Others
  • 7.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Point of Care Drug of Abuse (DOA) Testing Market: Regional Business Analysis

• 8.1. Regional Market Snapshot
• 8.2. North America
  • 8.2.1. North America Point of Care Drug of Abuse (DOA) Testing Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 8.2.2. U.S.
    • 8.2.2.1. U.S. Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.2.2.2. Key Country Dynamics
    • 8.2.2.3. Regulatory Framework
    • 8.2.2.4. Reimbursement Scenario
    • 8.2.2.5. Competitive Scenario
  • 8.2.3. Canada
    • 8.2.3.1. Canada Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.2.3.2. Key Country Dynamics
    • 8.2.3.3. Regulatory Framework
    • 8.2.3.4. Reimbursement Scenario
    • 8.2.3.5. Competitive Scenario
  • 8.2.4. Mexico
    • 8.2.4.1. Mexico Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.2.4.2. Key Country Dynamics
    • 8.2.4.3. Regulatory Framework
    • 8.2.4.4. Reimbursement Scenario
    • 8.2.4.5. Competitive Scenario
• 8.3. Europe
  • 8.3.1. Europe Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
  • 8.3.2. UK
    • 8.3.2.1. UK Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.3.2.2. Key Country Dynamics
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. Reimbursement Scenario
    • 8.3.2.5. Competitive Scenario
  • 8.3.3. Germnay
    • 8.3.3.1. Germany Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.3.3.2. Key Country Dynamics
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Reimbursement Scenario
    • 8.3.3.5. Competitive Scenario
  • 8.3.4. Spain
    • 8.3.4.1. Spain Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.3.4.2. Key Country Dynamics
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Reimbursement Scenario
    • 8.3.4.5. Competitive Scenario
  • 8.3.5. France
    • 8.3.5.1. France Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.3.5.2. Key Country Dynamics
    • 8.3.5.3. Regulatory Framework
    • 8.3.5.4. Reimbursement Scenario
    • 8.3.5.5. Competitive Scenario
  • 8.3.6. Italy
    • 8.3.6.1. Italy Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.3.6.2. Key Country Dynamics
    • 8.3.6.3. Regulatory Framework
    • 8.3.6.4. Reimbursement Scenario
    • 8.3.6.5. Competitive Scenario
  • 8.3.7. Denmark
    • 8.3.7.1. Denmark Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.3.7.2. Key Country Dynamics
    • 8.3.7.3. Regulatory Framework
    • 8.3.7.4. Reimbursement Scenario
    • 8.3.7.5. Competitive Scenario
  • 8.3.8. Sweden
    • 8.3.8.1. Sweden Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.3.8.2. Key Country Dynamics
    • 8.3.8.3. Regulatory Framework
    • 8.3.8.4. Reimbursement Scenario
    • 8.3.8.5. Competitive Scenario
  • 8.3.9. Norway
    • 8.3.9.1. Norway Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.3.9.2. Key Country Dynamics
    • 8.3.9.3. Regulatory Framework
    • 8.3.9.4. Reimbursement Scenario
    • 8.3.9.5. Competitive Scenario
• 8.4. Asia Pacific
  • 8.4.1. Asia Pacific Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
  • 8.4.2. Japan
    • 8.4.2.1. Japan Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.4.2.2. Key Country Dynamics
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Reimbursement Scenario
    • 8.4.2.5. Competitive Scenario
  • 8.4.3. China
    • 8.4.3.1. China Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.4.3.2. Key Country Dynamics
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Reimbursement Scenario
    • 8.4.3.5. Competitive Scenario
  • 8.4.4. India
    • 8.4.4.1. India Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.4.4.2. Key Country Dynamics
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Reimbursement Scenario
    • 8.4.4.5. Competitive Scenario
  • 8.4.5. South Korea
    • 8.4.5.1. South Korea Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.4.5.2. Key Country Dynamics
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Reimbursement Scenario
    • 8.4.5.5. Competitive Scenario
  • 8.4.6. Thailand
    • 8.4.6.1. Thailand Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.4.6.2. Key Country Dynamics
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Reimbursement Scenario
    • 8.4.6.5. Competitive Scenario
  • 8.4.7. Australia
    • 8.4.7.1. Australia Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.4.7.2. Key Country Dynamics
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Reimbursement Scenario
    • 8.4.7.5. Competitive Scenario
• 8.5. Latin America
  • 8.5.1. Latin America Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
  • 8.5.2. Brazil
    • 8.5.2.1. Brazil Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.5.2.2. Key Country Dynamics
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Reimbursement Scenario
    • 8.5.2.5. Competitive Scenario
  • 8.5.3. Argentina
    • 8.5.3.1. Argentina Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.5.3.2. Key Country Dynamics
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Reimbursement Scenario
    • 8.5.3.5. Competitive Scenario
• 8.6. MEA
  • 8.6.1. MEA Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
  • 8.6.2. South Africa
    • 8.6.2.1. South Africa Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.6.2.2. Key Country Dynamics
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Reimbursement Scenario
    • 8.6.2.5. Competitive Scenario
  • 8.6.3. Saudi Arabia
    • 8.6.3.1. Saudi Arabia Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.6.3.2. Key Country Dynamics
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Reimbursement Scenario
    • 8.6.3.5. Competitive Scenario
  • 8.6.4. UAE
    • 8.6.4.1. UAE Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.6.4.2. Key Country Dynamics
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Reimbursement Scenario
    • 8.6.4.5. Competitive Scenario
  • 8.6.5. Kuwait
    • 8.6.5.1. Kuwait Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.6.5.2. Key Country Dynamics
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Reimbursement Scenario
    • 8.6.5.5. Competitive Scenario

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Strategy Mapping
  • 9.2.1. NEW PRODUCT LAUNCH
  • 9.2.2. PARTNERSHIPS
  • 9.2.3. ACQUISITION
  • 9.2.4. COLLABORATION
  • 9.2.5. FUNDING
• 9.3. Key Company Market Share Analysis, 2024
• 9.4. Company Heat Map Analysis
• 9.5. Company Profiles
  • 9.5.1. ABBOTT
    • 9.5.1.1. Company Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. QUEST DIAGNOSTICS
    • 9.5.2.1. Company Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. THERMO FISHER SCIENTIFIC
    • 9.5.3.1. Company Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. ORASURE TECHNOLOGIES
    • 9.5.4.1. Company Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. SIEMENS HEALTHINEERS
    • 9.5.5.1. Company Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. F. HOFFMANN-LA ROCHE LTD.
    • 9.5.6.1. Company Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic Initiatives
  • 9.5.7. Dragerwerk AG & Co. KGaA
    • 9.5.7.1. Company Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Product Benchmarking
    • 9.5.7.4. Strategic Initiatives
  • 9.5.8. LABCORP (LABORATORY CORPORATION OF AMERICA HOLDINGS)
    • 9.5.8.1. Company Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Product Benchmarking
    • 9.5.8.4. Strategic Initiatives
  • 9.5.9. PREMIER BIOTECH, INC.
    • 9.5.9.1. Company Overview
    • 9.5.9.2. Financial Performance
    • 9.5.9.3. Product Benchmarking
    • 9.5.9.4. Strategic Initiatives